Replies to post #5148 on Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[ash111]

KTOV Solid DD,JB3729. Once approved, KIT-302 will be the only drug in the market able to claim simultaneous treatment of OA pain and treatment of hypertension.

World-wide sales of Celebrex® alone were $2.7 billion in 2014, ~$1B in 2015 (due to generic competition)w/ all side affects. Celebrex has major risks while KTOV has an improved celebrex. folks might drop celebrex and switch to Kitov drug and not worry about side affects. with the improved celebrex Pfizer could easily pass $2.4B even $3B sales IMO. This been talking over and over also by analysts predicted a blockbaster potential in the US alone.

A/o today market cap is $15m equal to Cash on hand. Kitov also has 53% ownership on another Company holds a breakthrough patent. Big undervalued if you ask me.
http://www.genengnews.com/gen-news-highlights/kitov-takes-majority-stake-in-tyrnovo-to-expand-pipeline-with-immunotherapeutic-candidate/81253704

NT219- registered Patent.

"A step toward development of drugs for diseases like Alzheimer's, Parkinson's and Huntington's". New compound for slowing the aging process can lead to novel treatments for brain diseases: http://www.innovations-report.com/html/reports/medicine-health/compound-slowing-aging-process-lead-treatments-223636.html